Anastassia Amaro, MD
Endocrinology, Diabetes & Metabolism · Philadelphia, PANPI 1013134659
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $12,333 of the $16,404 with a category attached, or 75.2%. Novo Nordisk accounts for 61.0% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $6,458, more than ten times the $368 reported in 2019.
Across 32 payments — averaging $512.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$10K
- AbbVie$3K
- Pfizer$2K
- Eli Lilly$841
- Astrazeneca UK Limited$135
- Abbott$67
- plus $72 from 2 others
Across 7 payments — averaging $7066.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$26K
- AstraZeneca$15K
- Aspire Bariatrics, Inc.$8K
What the payments were for
- Consulting fees$12,33375%
- Speaking & faculty fees$1,85011%
- Travel & lodging$1,1147%
- Food & beverage$1,1087%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $10,014 |
| AbbVie | 5 | $3,425 |
| Pfizer | 1 | $1,850 |
| Eli Lilly | 4 | $841 |
| Astrazeneca UK Limited | 1 | $135 |
| Abbott | 3 | $67 |
| Lilly USA, LLC | 2 | $46 |
| Tandem Diabetes Care, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,404 in reported general payments places this provider in the 85th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 221 | $308,306 |
| MounjaroTirzepatide | 161 | $233,538 |
| TrulicityDulaglutide | 67 | $104,084 |
| JardianceEmpagliflozin | 57 | $72,328 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $29,640 |
| FarxigaDapagliflozin Propanediol | 32 | $28,918 |
| Victoza 3-PakLiraglutide | 20 | $21,695 |
| Humalog Kwikpen U-100Insulin Lispro | 24 | $7,870 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $7,054 |
| Novolog FlexpenInsulin Aspart | 19 | $5,137 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $1,797 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 17 | $1,738 |
| Metformin Hcl ErMetformin Hcl | 94 | $1,445 |
| Metformin Hcl | 105 | $1,401 |
| SynthroidLevothyroxine Sodium | 16 | $1,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $46 | $337,621228 claims |
| Novo NordiskOzempic | $10,014 | $308,306221 claims |
| AbbVieSynthroid | $3,425 | $1,18316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Philadelphia
- Serge JabbourPhiladelphia$1.2M
- Jane MayrinPhiladelphia$628K
- Intekhab AhmedPhiladelphia$528K
- Mitchell LazarPhiladelphia$358K
- Michael RickelsPhiladelphia$65K
- Amna KhanPhiladelphia$39K
- Janna PraterPhiladelphia$22K
- Anne CappolaPhiladelphia$17K
- Monika ShirodkarPhiladelphia$15K
- Vijay BahlPittsburgh$998K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.